<DOC>
	<DOC>NCT00140452</DOC>
	<brief_summary>The use of Thalidomide in patients with ALS who have disease progression.</brief_summary>
	<brief_title>Phase II Study Using Thalidomide for the Treatment of ALS</brief_title>
	<detailed_description>Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of disease progression.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Clinically proven ALS Disease duration less than or equal to 5 years ALSFRSR score equal to or greater then 30 Patients with known deep venous thrombosis or hyper coagulable state will be excluded Patients with FVC less than 80%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>ALS</keyword>
</DOC>